Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Cartesian Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Details : The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of my...
Product Name : Descartes-08
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 13, 2023
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Cartesian Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Leerink Partners
Deal Size : $60.2 million
Deal Type : Private Placement
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Details : The combined company will focus on the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment ...
Product Name : Descartes-08
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 13, 2023
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Leerink Partners
Deal Size : $60.2 million
Deal Type : Private Placement
Lead Product(s) : Pegadricase,ImmTOR
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : $705.0 million
Deal Type : Licensing Agreement
Details : Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory g...
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : $75.0 million
October 31, 2023
Lead Product(s) : Pegadricase,ImmTOR
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : $705.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Xork,AT845
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Astellas Pharma
Deal Size : $350.0 million
Deal Type : Licensing Agreement
Details : SEL-018 (xork) is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for Late-Onset Pompe disease (LOPD) in ...
Product Name : SEL-018
Product Type : Antibody
Upfront Cash : $10.0 million
September 01, 2023
Lead Product(s) : Xork,AT845
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Astellas Pharma
Deal Size : $350.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pegadricase,SEL-110
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
Details : SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint ...
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : Pegadricase,SEL-110
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEL-302 is Adeno-Associated Virus (AAV) sterotype which consists of MMA-101 plus ImmTOR for the treatment of patients with methylmalonic acidemia (MMA).
Product Name : SEL-302
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEL-302 comprises ImmTOR in combination with MMA-101, and has the potential to mitigate unwanted immunogenicity to treat individuals with methylmalonic acidemia.
Product Name : SEL-302
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : SEL-302
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VTX-803,ImmTOR
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress
Details : Re-administration of AAV expressing MDR3 (VTX-803) treats progressive familial intrahepatic cholestasis type 3 (PFIC3) in juvenile Abcb4 -/- mice when co-administered with ImmTOR.
Product Name : VTX-803
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : VTX-803,ImmTOR
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MMA-101,ImmTOR
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Selecta Announces Publication of Data Evaluating AAV Vectors the Treatment
Details : In the study, MMA-101 performed in collaboration with the National Human Genome Research Institute, researchers evaluated the therapeutic efficacy of co-administration of ImmTOR and an AAV vector in a mouse model of MMA.
Product Name : MMA-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : MMA-101,ImmTOR
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : Takeda Pharmaceutical
Deal Size : $1,124.0 million
Deal Type : Licensing Agreement
Details : The collaboration leverages Selecta’s ImmTOR platform to enable redosing of transformative therapies and overcoming barriers to current efforts in AAV-driven gene therapy, as well as striving to address immunogenicity constraints and unmet patient need...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 10, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : Takeda Pharmaceutical
Deal Size : $1,124.0 million
Deal Type : Licensing Agreement